Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 6/20 | 0.45 |
| ▸ | MMP9 | P14780 | 6/20 | 0.45 |
| ▸ | MMP13 | P45452 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 5/20 | 0.43 |
| ▸ | MMP7 | P09237 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060475 | 0.87 | ALDH1A1 (0.40) | MMP2CA12CA14CA2MMP1 | |
| SCHEMBL26460446 | 0.82 | MMP2 (0.50) | MMP2CA12CA14CA2PLCG1 | |
| SCHEMBL32038 | 0.82 | MMP2 (0.55) | MMP2CA12CA14CA2PLCG1 | |
| SCHEMBL14850017 | 0.82 | MMP2 (0.50) | MMP2CA12CA14CA2PLCG1 | |
| SCHEMBL10060466 | 0.80 | CA12 (0.46) | MMP2CA12CA14CA2MMP1 | |
| SCHEMBL12674211 | 0.79 | MMP2 (0.47) | MMP2CA12CA14CA2PLCG1 | |
| SCHEMBL13813079 | 0.79 | MMP2 (0.47) | MMP2CA12CA14CA2PLCG1 | |
| SCHEMBL178444 | 0.78 | GAA (0.56) | MMP2CA12CA2MMP1MMP9 | |
| SCHEMBL2657775 | 0.78 | ALDH1A1 (0.36) | MMP2CA12CA14CA2MMP1 | |
| SCHEMBL14520771 | 0.78 | ENPP2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250243220-A1 | ATR INHIBITORS | APREA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023235305-A2 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2022251472-A9 | METHODS AND DEVICES FOR REAL-TIME WORD AND SPEECH DECODING FROM NEURAL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023201320-A1 | ATR INHIBITORS | Atrin Pharmaceuticals LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1773105-A2 | Multilayer printed circuit board | IBIDEN CO., LTD. (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-0683172-B1 | 11,21-Bisphenyl-19-norpregnane derivatives | AKZO NOBEL NV (NL) | 1997-08-13 | — | — | EP | disclosed |
| US-5620966-A | ANTIGLUOCORTICOID ACTIVITY | AKZO NOBEL N.V. (NL) | 1997-04-15 | — | — | US | disclosed |
| EP-0683172-A1 | 11,21-Bisphenyl-19-norpregnane derivatives | Akzo Nobel N.V. (NL) | 1995-11-22 | — | — | EP | disclosed |
| EP-0412387-B1 | Diarylacetylenes, their process and use | BASF AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-5087637-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0412387-A2 | Diarylacetylenes, their process and use | BASF Aktiengesellschaft (DE) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | MMP2 1701/4885CA12 4213/4885CA14 3288/4885 |
| US-20250243220-A1 | ATR INHIBITORS | ATR, CHEK1, CHEK2 | MMP2 4274/4885CA12 4447/4885CA14 4539/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MMP2 487/4885CA12 4569/4885CA14 4355/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | MMP2 2022/4885CA12 3963/4885CA14 4181/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | MMP2 3662/4885CA12 3436/4885CA14 3271/4885 |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | MMP2 1701/4885CA12 4213/4885CA14 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.